Case report observes bluish nail discoloration in a chronic myeloid leukemia patient treated with imatinib mesylate, highlighting rare cutaneous toxicity.
Nail toxicity is an uncommon cutaneous adverse effect of imatinib mesylate. Here, we have described a 45-year-old female, a diagnosed case of Philadelphia positive chronic myeloid leukemia, who was on imatinib mesylate for the past 3 months and developed bluish discoloration of the nails. This discoloration was related to the drug imatinib mesylate because the patient was only on imatinib and thyroxine medication. No any other skin-related diseases was present, which can lead to her nail changes. [Natl J Physiol Pharm Pharmacol 2020; 10(12.000): 1160-1162]
No takes yet. Share an insight, caveat, or question.
Damor et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: